aging population Archives – Varsity Branding

Tag: aging population

Aging has long been framed as a slow narrowing of possibilities, but that perspective is beginning to shift. In a recent episode of Varsity’s podcast, Roundtable Talk, Derek sat down with Colin Milner, founder and CEO of the International Council on Active Aging, whose work has helped redefine aging as a dynamic, engaged and opportunity-filled stage of life.

In their conversation, Derek and Colin explored why changing perceptions around aging takes time, the growing importance of closing the gap between lifespan and health span and how simple behaviors like staying active and curious can have outsized impact. Check out the full episode here.

WHY HAS IT BEEN SO HARD TO CHANGE THE NARRATIVE THAT AGING EQUALS DECLINE?

It really comes down to time. It was a massive wave going in one direction, and changing that takes decades. I was told it would take 30 years to make an impact, and now, 25 years in, wellness is everywhere. Things take time to change, and many people don’t stay in it long enough to see the results.

WHAT DOES “ACTIVE AGING” MEAN TODAY?

The definition hasn’t changed. It’s about being engaged in life, in all areas of life. What has changed is the implementation. If you’re engaged, the ripple effect begins to happen. You become more socially connected, more physically active and more involved overall. Engagement drives everything.

WHAT HAPPENS WHEN PEOPLE START SEEING AGING AS GROWTH INSTEAD OF DECLINE?

Everything changes. You start looking at possibilities instead of limitations. The world opens up to you instead of closing off. When systems are in place to support that mindset, people have the opportunity to grow rather than feel like things are being taken away from them.

WHY SHOULD WE FOCUS MORE ON HEALTH SPAN, NOT JUST LIFESPAN?

If we don’t shrink the health span gap, all we’re doing is extending life and extending years of ill health. Right now, that gap is about 12.4 years. People want to live longer, but not in poor health. We have to close that gap or longevity doesn’t really mean what we think it does.

WHAT ARE MARKETERS GETTING WRONG ABOUT OLDER ADULTS?

Ageism. Most marketers are younger and not excited about creating for an older audience. But two older adults control 70 to 75% of disposable income. It’s a massive opportunity that’s still being overlooked because of outdated assumptions about what aging looks like.

QUOTES

“Our vision was very simple, and that was to help change the way we age. Sounds easy—lot harder, because virtually everything we do impacts the way we age.” (Colin)

“It will take you about 30 years to have an impact… and now, 25 years in, wellness is everywhere. Things take time to change.” (Colin)

“It’s about being engaged in life, in all areas of life… if you’re engaged, the ripple effect begins to happen.” (Colin)

“We are driving change as opposed to responding to it—and we’re speaking with our pocketbook.” (Colin)

“When you see aging as growth, everything changes. The world opens up to you as opposed to closing off.” (Colin)

“No one is guaranteed longevity. We need to earn it by living a better quality of life.” (Colin)

“If we don’t shrink the health span gap, all we’re doing is extending our life—and extending years of ill health.” (Colin)

“Put on your shoes and go for a walk… get out of the house and be curious about life, and a lot of other things begin to fall into place.” (Colin)

“Curiosity is the spice of life… everyone I’ve spoken with, that has been a key element in their success.” (Colin)

“Senior living communities should be centers for discovery.” (Colin)

“Two older adults have 70 to 75% of the disposable income—and yet marketers still overlook them.” (Colin)

“No two people age the same way or at the same rate… personalization enables people to embrace their potential.” (Colin) 

NOTES

Colin Milner is the founder and CEO of the International Council on Active Aging (ICAA) and a leading voice in the global longevity movement. For more than two decades, he has challenged outdated perceptions of aging and advocated for active, engaged lifestyles at every stage of life.

The International Council on Active Aging is a mission-driven organization focused on helping older adults live better, longer lives. Through research, education and tools, ICAA supports senior living communities and organizations worldwide in advancing wellness, engagement and quality of life.

Founded nearly 25 years ago, ICAA operates in more than 50 countries and works with thousands of senior living communities. The organization provides research, benchmarking tools and guidance to help operators improve outcomes, including demonstrating the ROI of wellness programs through increased resident retention and engagement.

Milner emphasized that aging is not defined by decline but by engagement, and that staying active across physical, social and mental dimensions creates a ripple effect that improves overall well-being.

He noted that shifting perceptions around aging takes time, but meaningful progress has been made as wellness has become more widely accepted and integrated into everyday life.

Milner highlighted the critical gap between lifespan and health span, stressing that without improving quality of life, longer lifespans simply extend years of poor health.

He encouraged simple behavior changes like staying active and maintaining curiosity, pointing to curiosity as a key driver of long-term fulfillment and success.

He described baby boomers as a generation driving change, with higher expectations and greater willingness to spend on experiences and products that support quality of life.

Milner pointed out that older adults control a significant share of disposable income, yet are often overlooked by marketers due to persistent ageism and outdated assumptions.

He advocated for rethinking senior living communities as centers for discovery, where residents can continue exploring interests, building connections and redefining their capabilities.

He also stressed the importance of personalization in aging, noting that no two individuals age the same way and that tailored approaches are essential to helping people reach their full potential.

————-

The following is Part 2 of a two-part series (see part one here) exploring how pharmacogenetic (PGx) testing can help senior living communities navigate medication conversations and support more personalized care. The series is written by Dr. Troy Veale, CEO of PHD Laboratory, a healthcare innovator with more than 25 years of experience in behavioral health and over a decade in laboratory science focused on advancing precision medicine and improving patient outcomes.

————-

In Part 1, we explored why medication conversations matter in senior living environments. In Part 2, we turn to the clinical side of pharmacogenetic (PGx) testing, what it is, what it is not, and why it holds particular relevance for aging populations.

WHAT PGx TESTING ACTUALLY EVALUATES

Pharmacogenetic testing analyzes specific genes that influence how medications are metabolized. Using a non-invasive cheek swab, laboratories evaluate genetic markers related to drug-processing enzymes, particularly those that impact common prescriptions used in aging adults.

Results may indicate whether an individual is likely to:

  • Metabolize a medication too quickly (reducing effectiveness)
  • Metabolize it too slowly (increasing side effect risk)
  • Process it as expected
  • Benefit from alternative medication classes

The goal is not to dictate therapy but to provide additional data to support provider judgment.

WHY AGING POPULATIONS BENEFIT FROM PERSONALIZATION

Older adults are more susceptible to adverse drug reactions for several reasons:

  • Decreased liver and kidney function
  • Changes in body composition
  • Multiple coexisting health conditions
  • Polypharmacy (use of multiple medications)

Research consistently shows that adverse drug events are a leading cause of emergency department visits among older adults. Even when medications are appropriately prescribed, genetic variation can influence response.

PGx testing brings that variability into clearer focus.

ADDRESSING COMMON MYTHS

Myth 1: PGx testing is only for complex cases.
In reality, many commonly prescribed medications,  including those for cardiovascular health, depression, pain, and neurology — have pharmacogenetic considerations.

Myth 2: Stable patients don’t need this information.
Even stable residents may benefit from minimizing long-term risk or identifying lower-risk alternatives.

Myth 3: It replaces physician expertise.
PGx testing enhances decision-making. Providers interpret results within the context of medical history and clinical presentation.

Myth 4: It is invasive or risky.
The test requires only a simple cheek swab.

BENEFITS ACROSS STAKEHOLDERS

For providers:

  • Additional prescribing insight
  • Support for medication adjustments
  • Alignment with evidence-informed care

For senior living teams:

  • Stronger educational positioning
  • Confidence in discussing holistic care
  • Alignment with preventative models

For families:

  • Greater transparency
  • Reduced uncertainty
  • Peace of mind

Medication conversations become proactive rather than reactive.

PRIVACY, COVERAGE AND NEXT STEPS

Your DNA is used only to analyze how your body processes medications. PHD Laboratory does not sell, share, or store your DNA for any other purpose. We are CLIA and COLA certified and fully compliant with HIPAA privacy laws, ensuring your genetic information is protected and confidential at all times.

PGx testing is covered by Medicare Part B for eligible patients and may also be paid for using FSA/HSA funds, CareCredit, or private pay options.

For questions, educational information, or to order a PGx test, please visit the PHD Laboratory website or email info@phdlaboratory.com.

————-

The following is Part 1 of a two-part series exploring how pharmacogenetic (PGx) testing can help senior living communities navigate medication conversations and support more personalized care. The series is written by Dr. Troy Veale, CEO of PHD Laboratory, a healthcare innovator with more than 25 years of experience in behavioral health and over a decade in laboratory science focused on advancing precision medicine and improving patient outcomes.

————-
In senior living, some of the most important conversations don’t happen on a tour, they happen around medications.

Families ask questions quietly:

  • Why is Mom more tired lately?
  • Is this medication causing confusion?
  • Why does this prescription work for one resident but not another?

Medication management is often treated as a clinical back-office issue. But in reality, it directly affects resident satisfaction, outcomes, staff confidence, and family trust.

For senior living sales teams, executive directors, nurses, and caregivers, medication conversations present both a challenge and an opportunity. The challenge is complexity. The opportunity is education.

One emerging tool helping shift these discussions is pharmacogenetic (PGx) testing, not as a sales pitch, and not as a replacement for physician oversight, but as a framework for clearer conversations.

Why Medication Conversations Feel Overwhelming

Older adults frequently manage multiple chronic conditions, cardiovascular disease, diabetes, depression, chronic pain, neurological disorders. It is not uncommon for residents to take five, ten, or even more medications daily.

With aging comes physiological changes that affect how the body absorbs, metabolizes, and eliminates drugs. These changes can increase the risk of:

  • Adverse drug reactions
  • Falls and dizziness
  • Increased confusion
  • Medication non-adherence due to side effects
  • Avoidable hospitalizations

Families often assume these risks are simply “part of aging.” Teams sometimes assume side effects are unavoidable. Providers do their best with the information available.

But what if medication conversations didn’t have to start from a place of guesswork?

A Shift Toward Personalization

PGx testing evaluates how a person’s genetics may influence the way certain medications are processed in the body. It doesn’t diagnose disease. It doesn’t predict future illness. It provides insight into how medications may interact with an individual’s metabolic profile.

For senior living professionals, the most powerful part of PGx testing isn’t the lab result, it’s the conversation it opens.

It creates space to ask:

  • Is this medication optimal for this individual?
  • Could side effects be reduced?
  • Are there alternatives that may align better?
  • How can we support safer prescribing conversations?

These are not clinical determinations made by sales staff or caregivers. They are informed discussions that support provider evaluation and collaborative care planning. 

Trust Is Built Through Transparency

Senior living is built on trust. Families are not just choosing a community; they are choosing partners in care.

When medication conversations are proactive rather than reactive, families feel:

  • Heard
  • Educated
  • Involved
  • Reassured

Communities that introduce the idea of personalized medication discussions demonstrate alignment with preventative and value-based care models.

Sales teams are uniquely positioned here. They can frame PGx testing as a supportive educational resource, one that enhances provider decision-making and resident well-being.

Rather than saying, “We offer genetic testing,” the conversation becomes:

“We believe in helping families feel confident in every aspect of care — including medications.”

Removing Barriers, Not Adding Complexity

One concern often raised is whether introducing PGx testing adds another layer of complexity to an already overwhelming process. The opposite can be true.

By helping providers evaluate medication suitability earlier rather than later, PGx testing may reduce future medication adjustments, side effects, or avoidable emergency visits. It simplifies long-term decision-making by introducing clearer data into the process.

For caregivers and daughters like Michele, who recently navigated placing her own mother into senior living, clarity around medications is deeply personal. Families want assurance that their loved one is not simply “trying medications”, but receiving informed, thoughtful care.

PGx testing supports that reassurance.

A New Category of Conversation

Senior living has evolved to include partnerships in move management, downsizing, care coordination, and wellness programming. Medication personalization is a natural extension of holistic senior care.

This isn’t about replacing physicians. It isn’t about overstepping clinical boundaries. It’s about strengthening education, transparency, and collaboration.

In Part 2, we will explore the clinical foundation behind PGx testing, how it works, common myths, and why it continues gaining traction in aging populations.

Privacy, Coverage, and Next Steps

Your DNA is used only to analyze how your body processes medications. PHD Laboratory does not sell, share, or store your DNA for any other purpose. We are CLIA and COLA certified and fully compliant with HIPAA privacy laws, ensuring your genetic information is protected and confidential at all times.

PGx testing is covered by Medicare Part B for eligible patients and may also be paid for using FSA/HSA funds, CareCredit, or private pay options.

For questions, educational information, or to order a PGx test, please visit the PHD Laboratory website or email info@phdlaboratory.com.
Subscribe to
Varsity Prime

Varsity has a podcast!

Our new podcast about longevity and aging offers fresh perspectives and interviews with industry leaders.